# 2026年1月4日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 垂体神经内分泌肿瘤中错配修复系统表达的新见解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41483255)
**期刊：** Endocrine pathology
**PMID：** 41483255
**DOI：** 10.1007/s12022-025-09896-7

### 第一部分 原文与翻译

**英文原标题：** New Insights from the Expression of the Mismatch Repair System in Pituitary Neuroendocrine Tumors.

> **英文摘要：**
> Although defects in the mismatch repair (MMR) system have been occasionally reported in aggressive/metastatic pituitary neuroendocrine tumors (PitNETs), the potential role of MMR dysregulation in pituitary tumorigenesis is largely unknown. This study aimed to evaluate the expression of the four key MMR components in a large series of PitNETs. MMR gene expression was studied by RT-qPCR in 127 tumors (54 PIT1, 51 SF1, 22 TPIT), and semi-quantitative immunohistochemistry (score 0-12) in selected cases (n=46). MSH2/6 and MLH1 promoters methylation was studied in 96 tumors. Except for MLH1, tumor lineage of origin was the most significant factor influencing MMR transcripts (P=0.005, <0.001 and 0.039 for MSH2/6 and PMS2, respectively), the highest levels being observed in SF1 tumors. Within subgroups, MMR transcripts were significantly lower in large/invasive PIT1 and in functioning TPIT tumors. MSH2 promoter methylation was occasionally associated with reduced MSH2 expression. Global loss of MSH6 (score 0), defining MMR deficiency, was observed in a single silent lactotroph PitNET, unrelated to the Lynch's syndrome. Near global loss involving MSH6, MSH2 or PMS2 (score 1) was observed in 5 tumors (1 lactotroph, 1 SF1, 3 TPIT). MMR mutations were excluded in 4/5 cases but 2 had LOH at MSH2/MSH6 loci. Heterogeneous immunostaining for any MMR (score 2-4) was also observed in 15 cases. In conclusion, MMR deficiency was rarely observed (2.2%) but reduced MMR expression could be found, especially in functioning corticotroph and invasive lactotroph tumors. The molecular mechanisms and prognostic significance of such findings would deserve further investigation.

> **中文摘要：**
> 尽管在侵袭性或转移性垂体神经内分泌肿瘤（PitNETs）中偶尔报告有错配修复（MMR）系统的缺陷，但MMR系统失调在垂体肿瘤发生中的潜在作用仍基本未知。本研究旨在评估大量PitNETs中四个关键MMR组分的表达情况。研究通过RT-qPCR检测了127例肿瘤（其中PIT1型54例、SF1型51例、TPIT型22例）中的MMR基因表达，并在部分病例（n=46）中采用半定量免疫组化（评分0–12）。在96例肿瘤中检测了MSH2/6和MLH1启动子甲基化状态。除MLH1外，肿瘤谱系是影响MMR转录本水平的最显著因素（MSH2/6和PMS2的P值分别为0.005、<0.001及0.039），其中在SF1型肿瘤中检测到最高水平。在分型亚组中，大体积或侵袭性PIT1型以及功能性TPIT型肿瘤中MMR转录本明显较低。MSH2启动子甲基化偶尔与MSH2表达降低相关。全局性MSH6丢失（评分0），定义为MMR缺陷，被观察到于一例无症状泌乳细胞PitNET，与林奇综合征无关。涉及MSH6、MSH2或PMS2的近全局性丢失（评分1）在5例肿瘤中观察到（包括1例泌乳细胞型、1例SF1型和3例TPIT型）。在5例中有4例排除了MMR基因突变，但其中2例在MSH2/MSH6位点存在杂合性缺失。任一MMR分子的免疫染色异质性（评分2–4）也在15例中观察到。总之，MMR缺陷较为罕见（2.2%），但可检测到MMR表达降低，尤其在功能性促肾上腺皮质激素细胞瘤和侵袭性泌乳细胞瘤中。此类发现的分子机制及其预后意义尚需进一步研究。

### 第二部分 AI 大师评价

该研究系统性分析了垂体神经内分泌肿瘤中错配修复系统的基因与蛋白表达特征，结合RT-qPCR、免疫组化及甲基化分析，揭示MMR表达受肿瘤谱系类型显著影响。结果显示MMR缺陷极为罕见，但在特定功能型或侵袭型亚群中存在表达下降，提示其可能参与肿瘤生物学行为。研究在领域内提供了新的分子层面证据，具有一定创新性；然而其样本仍需在更大规模及机制层面得到验证。

---

## 2. 《胸部肿瘤学杂志》创刊二十周年系列：外科篇

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41483000)
**期刊：** Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
**PMID：** 41483000
**DOI：** 10.1016/j.jtho.2025.11.020

### 第一部分 原文与翻译

**英文原标题：** Journal of Thoracic Oncology 20th Anniversary Series Surgery.

> **英文摘要：**
> In the last 20 years, major changes have occurred in the diagnosis and management of thoracic oncologic pathology. Furthermore, thoracic surgery has undergone considerable changes since the inception of the Journal of Thoracic Oncology in 2006. Regarding staging of lung cancer, pleural mesothelioma, and thymic epithelial tumors, several revisions were implemented in the TNM classification. The recently published ninth edition represents a tremendous effort of the Staging and Prognostic Factors Group of the International Association for the Study of Lung Cancer to analyze worldwide survival data and to validate the proposed changes in newly designed categories. Complete resection of a lung cancer remains an underestimated but important prognostic factor, and current attention is directed to technical resectability within multimodality therapy for locoregional advanced lung cancer. Integration of surgery within protocols of neoadjuvant, adjuvant, and perioperative therapies is further evaluated to determine the optimal therapeutic strategy. For smaller lesions less than or equal to 2 cm, sublobar resection, comprising segmentectomy and wide wedge excision, has been proven to be an alternative to lobectomy in specific subgroups. In the last 20 years, minimally invasive techniques have been introduced to provide new approaches to the thoracic cavity, especially for early stage lung cancer. Interventions performed by video- or robotic-assisted thoracic surgery are associated with a clear clinical benefit without compromising oncologic outcome. The role of thoracic surgery for resectable lung cancer cases has been firmly established, and surgery has become an integral part of multimodality therapy, but undoubtedly, further refinements will be made in the forthcoming 20 years!

> **中文摘要：**
> 在过去的二十年中，胸部肿瘤疾病的诊断与管理发生了重大变化。此外，自2006年《胸部肿瘤学杂志》创刊以来，胸外科也经历了显著的发展。关于肺癌、胸膜间皮瘤和胸腺上皮肿瘤的分期，TNM分期系统进行了多次修订。最近发布的第九版TNM分期是国际肺癌研究协会分期与预后因素组为分析全球生存数据并验证新设计分类中所提出变更所作出的巨大努力。肺癌的完全切除仍然是一个被低估但重要的预后因素，目前的研究重点集中在局部晚期肺癌多模式治疗中的技术可切除性。外科手术在新辅助、辅助及围手术期治疗方案中的整合正在继续评估，以确定最佳治疗策略。对于直径小于或等于2厘米的小病灶，经肺段切除或宽楔形切除的亚肺叶切除术已被证实在特定人群中可作为叶切除术的替代选择。在过去二十年中，微创技术被引入胸腔手术，为治疗早期肺癌提供了新的方法。通过视频辅助或机器人辅助胸外科实施的手术显示出明确的临床获益，同时并不影响肿瘤学结局。胸外科在可切除肺癌病例中的作用已被牢固确立，手术已成为多模式治疗的重要组成部分，但毫无疑问，在未来二十年内仍将继续获得进一步改进。

### 第二部分 AI 大师评价

本文综述了过去二十年来胸外科在胸部肿瘤诊疗中的演变，尤其聚焦于肺癌分期修订、完全切除的重要性及多模式治疗结合的进展。作者强调微创及机器人辅助技术在提高早期肺癌患者预后中的关键作用，并指出亚肺叶切除在特定患者亚群中的合理应用。该文系统总结了全球数据支撑下的分期与手术策略优化，对未来胸外科发展方向提供了重要参考。其创新之处在于整合全球预后数据与技术进展，但仍需进一步验证长期疗效及可推广性。

---

## 3. MajesTEC 研究：teclistamab 在复发和/或难治性多发性骨髓瘤中的研究结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482569)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41482569
**DOI：** 10.1038/s41571-025-01116-9

### 第一部分 原文与翻译

**英文原标题：** MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献报道了 MajesTEC 临床研究中 teclistamab 在复发或难治性多发性骨髓瘤患者中的治疗结果。作为双特异性 T 细胞连接抗体，teclistamab 通过同时靶向 BCMA 和 CD3 激活免疫系统以清除肿瘤细胞。尽管尚无摘要提供，但由期刊定位和题目可推测该研究总结了治疗应答率、安全性及长期疗效的最新进展。其意义在于为既往治疗失败的骨髓瘤患者提供新的免疫治疗选项，同时提示仍需进一步验证疗效持久性与不良事件管理。

---

## 4. Vebreltinib 对 MET 扩增型非小细胞肺癌具有疗效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482568)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41482568
**DOI：** 10.1038/s41571-025-01117-8

### 第一部分 原文与翻译

**英文原标题：** Vebreltinib effective in MET-amplified NSCLC.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该报道概要指出，Vebreltinib 在 MET 基因扩增型非小细胞肺癌中表现出疗效，暗示其可能成为该分子特征人群的重要靶向治疗药物。尽管暂无详细摘要与实验数据，但信息表明研究强调了 MET 通路抑制在精准医疗中的价值。该成果为未来针对 MET 异常肺癌的治疗策略提供了新的方向，后续仍需验证其临床获益与安全性。

---

## 5. 机制性洞见使癌症恶病质成为可靶向的综合征。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482565)
**期刊：** Nature medicine
**PMID：** 41482565
**DOI：** 10.1038/s41591-025-04109-4

### 第一部分 原文与翻译

**英文原标题：** Mechanistic insights make cancer cachexia a targetable syndrome.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该文发表于《Nature Medicine》，聚焦癌症恶病质的分子与机制性理解，并提出其作为潜在可干预靶点的观点。标题暗示作者可能整合了多层次的机制研究，如代谢、免疫和炎症路径，为此前缺乏有效治疗策略的恶病质提供新的研究方向。文章的亮点在于将基础机制与临床靶向性紧密结合，具备创新启发意义。其局限可能在于实验验证或临床数据的成熟度尚待确认。

---

## 6. 基于生成式人工智能的低剂量数字减影血管造影在术中辐射剂量降低中的应用：一项随机对照试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482562)
**期刊：** Nature medicine
**PMID：** 41482562
**DOI：** 10.1038/s41591-025-04042-6

### 第一部分 原文与翻译

**英文原标题：** Generative AI-based low-dose digital subtraction angiography for intra-operative radiation dose reduction: a randomized controlled trial.

> **英文摘要：**
> Digital subtraction angiography (DSA) devices guide procedures across numerous diseases, performed on more than 100,000 patients daily worldwide. However, these procedures expose patients and healthcare providers to radiation, increasing the risk of health issues. Despite many low-dose DSA imaging methods proposed, none have been prospectively clinically validated. In this study, 46,829 patients (over 5 million DSA images) from 70 centers were used to iterate our previously developed generative artificial intelligence system (named GenDSA-V2). A total of 1,068 patients (533 in intervention arm and 535 in control arm), with suspected cerebral aneurysms (n = 435), lung cancer (n = 417) or advanced liver cancer (n = 216), meeting surgical criteria, were enrolled to validate the GenDSA-V2. The primary outcome was radiation dose, while secondary outcomes included efficiency, operation time and intraoperative complications. Group assignments were blinded to patients, surgeons and investigators, while technicians were aware but not involved in data collection or analysis. The GenDSA-V2 group showed substantially reduced radiation exposure, with an air kerma (AK) of 151.3 ± 125.1 mGy compared to 457.4 ± 407.4 mGy in the standard clinical protocols (SCP) group (mean difference = -306.1 mGy, 95% confidence interval (CI) = -342.3 to -269.9, P < 0.001 for superiority) and a dose-area product (DAP) of 4009.7 ± 2767.9 μGy m versus 12531.6 ± 9145.9 μGy m (mean difference = -8521.9 μGy m, 95% CI = -9333.1 to -7710.7, P < 0.001 for superiority). Mean operation time was 33.1 ± 10.8 min in the SCP group and 34.8 ± 11.8 min in the GenDSA-V2 group (mean difference = 1.7 min, 95% CI = 0.3 to 3.1, P < 0.001 for noninferiority). Complication rates were similar (SCP = 8.1%, GenDSA-V2 = 7.5%, mean difference = -0.6%, 95% CI = -3.8% to 2.6%, P < 0.001 for noninferiority). The GenDSA system reduces radiation exposure to both physicians and patients by approximately two-thirds during DSA-guided procedures, demonstrating substantial clinical and translational value. Chinese Clinical Trial Registry: ChiCTR2400084789 .

> **中文摘要：**
> 数字减影血管造影（DSA）设备被广泛用于多种疾病的手术引导，每日全球有超过10万名患者接受此类操作。然而，这些操作会使患者及医护人员暴露于辐射之下，从而增加健康风险。尽管已提出多种低剂量DSA成像方法，但尚无一种经过前瞻性临床验证。在本研究中，研究团队利用来自70个中心的46,829名患者（超过500万张DSA图像）迭代优化了先前开发的生成式人工智能系统（命名为GenDSA-V2）。共有1,068名符合手术条件的患者纳入验证，其中干预组533人，对照组535人，疑似脑动脉瘤患者435例、肺癌患者417例、晚期肝癌患者216例。主要研究终点为辐射剂量，次要终点包括效率、手术时间及术中并发症。患者、外科医生及研究者均对分组情况保持盲态，而技术人员知情但未参与数据收集或分析。结果显示，GenDSA-V2组的辐射暴露显著降低，空气克马（AK）为151.3 ± 125.1 mGy，而标准临床方案（SCP）组为457.4 ± 407.4 mGy（平均差=-306.1 mGy，95%置信区间：-342.3至-269.9，P<0.001，显示优效性）；剂量面积乘积（DAP）为4009.7 ± 2767.9 μGy·m，而SCP组为12531.6 ± 9145.9 μGy·m（平均差=-8521.9 μGy·m，95%置信区间：-9333.1至-7710.7，P<0.001，显示优效性）。SCP组平均手术时间为33.1 ± 10.8分钟，GenDSA-V2组为34.8 ± 11.8分钟（平均差=1.7分钟，95%置信区间：0.3至3.1，P<0.001，显示非劣效性）。并发症发生率相近（SCP=8.1%，GenDSA-V2=7.5%，平均差=-0.6%，95%置信区间：-3.8%至2.6%，P<0.001，显示非劣效性）。GenDSA系统在DSA引导手术中可使医生和患者的辐射暴露量减少约三分之二，体现出显著的临床及转化价值。中国临床试验注册号：ChiCTR2400084789。

### 第二部分 AI 大师评价

该研究通过多中心随机对照试验验证了生成式人工智能在低剂量数字减影血管造影中的临床应用价值。研究显示，GenDSA-V2系统在保持图像质量与手术效率不劣的前提下，显著降低了医患双方的辐射暴露量。其样本量巨大、设计科学，为人工智能在介入影像学中的临床转化提供了强有力证据。研究创新性突出，但未来仍需评估其在其他疾病类型及不同设备环境下的普适性与长期安全性。

---

## 7. 自体多抗原靶向T细胞治疗胰腺癌：一项I/II期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482561)
**期刊：** Nature medicine
**PMID：** 41482561
**DOI：** 10.1038/s41591-025-04043-5

### 第一部分 原文与翻译

**英文原标题：** Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.

> **英文摘要：**
> T cell therapy has proven challenging for pancreatic ductal adenocarcinoma (PDAC), partly due to heterogeneous expression of tumor-associated antigens (TAAs). To address tumor heterogeneity and mitigate immune evasion, an ex vivo expanded, polyclonal, T helper 1 cell-polarized T cell product targeting five TAAs-PRAME, SSX2, MAGEA4, Survivin and NY-ESO-1-was developed. These antigens were chosen based on their tumor specificity, oncogenicity, immunogenicity and level of expression. In a phase 1/2 trial, this autologous nonengineered T cell product was administered (1 × 10 cells m per infusion) monthly to patients with advanced PDAC responding (arm A, n = 13) or refractory (arm B, n = 12) to first-line chemotherapy or with resectable disease (arm C, n = 12). Primary endpoints were safety and feasibility of completing six infusions, whereas exploratory efficacy endpoints included persistence and evaluating the relationship between clinical benefit and the expansion of the infused effector T cells, as well as the induction of de novo immune responses. Of 56 participants procured, 37 were infused, with only 1 treatment-related serious adverse event. Disease control rates in arms A and B were 84.6% (95% confidence interval: 54.6-98.1%) and 25% (95% confidence interval: 5.5-57.2%), respectively. In arm C, two of nine resected participants remained disease free after 66 months of follow-up. The infused cells persisted up to 12 months posttreatment and elevated levels of tumor-directed T cells were detected during dosing (P = 0.027) and follow-up in responders compared to nonresponders. Clinical outcomes correlated with peripheral expansion of functional TAA-targeted T cell clones and treatment-emergent antigen spreading. Thus, further investigation of this approach, either as a single agent or combined with other complementary modalities, is warranted (ClinicalTrials.gov identifier: NCT03192462 ).

> **中文摘要：**
> T细胞治疗在胰腺导管腺癌（PDAC）中被证明具有挑战性，部分原因是肿瘤相关抗原（TAA）表达的异质性。为应对肿瘤异质性并减轻免疫逃逸，研究者开发了一种体外扩增的多克隆、Th1极化的T细胞制剂，靶向五种TAA——PRAME、SSX2、MAGEA4、Survivin 和 NY-ESO-1。这些抗原的选择基于其肿瘤特异性、致癌性、免疫原性及表达水平。在一项I/II期临床试验中，这种自体、非工程化的T细胞制剂按月给药（每次输注1×10ⁿ个细胞/m），用于对一线化疗有反应（A组，n=13）、化疗难治（B组，n=12）或可切除疾病（C组，n=12）的晚期PDAC患者。主要终点为安全性及完成六次输注的可行性，探索性疗效终点包括细胞持续性，以及评估临床获益与输注效应T细胞扩增及新发免疫应答诱导之间的关系。在56名受试者中，有37人接受输注，仅1例发生治疗相关的严重不良事件。A组与B组的疾病控制率分别为84.6%（95%置信区间：54.6–98.1%）和25%（95%置信区间：5.5–57.2%）。在C组中，9名接受切除的受试者中有2人在66个月随访后仍无病生存。输注细胞在治疗后可持续存在长达12个月，在应答者中，给药期间（P=0.027）及随访阶段检测到更高水平的肿瘤靶向T细胞。临床结局与功能性TAA靶向T细胞克隆的外周扩增及治疗诱导的抗原扩散相关。因此，该策略无论作为单药治疗还是与其他互补疗法联合使用，均值得进一步研究（ClinicalTrials.gov编号：NCT03192462）。

### 第二部分 AI 大师评价

本研究通过开发靶向五种肿瘤相关抗原的自体多抗原T细胞制剂，探索胰腺导管腺癌免疫治疗的新方向。试验显示，该治疗具有良好的安全性和可行性，部分患者获得了疾病控制和持久的免疫应答。结果提示功能性T细胞克隆的扩增与临床益处密切相关，并伴有抗原扩散现象，体现了治疗的免疫学深度反应。其创新点在于非基因工程化、多抗原靶向的策略，可为免疫耐药性肿瘤带来新思路，但样本量有限及长期效果仍需验证。

---

## 8. 无需RNA三级结构预测小分子–RNA相互作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482542)
**期刊：** Nature biotechnology
**PMID：** 41482542
**DOI：** 10.1038/s41587-025-02942-z

### 第一部分 原文与翻译

**英文原标题：** Predicting small molecule-RNA interactions without RNA tertiary structures.

> **英文摘要：**
> Small molecules can bind RNAs to regulate their fate and functions, providing promising opportunities for treating human diseases. However, current tools for predicting small molecule-RNA interactions (SRIs) require prior knowledge of RNA tertiary structures. Here we present SMRTnet, a deep learning method that uses multimodal data fusion to integrate two large language models with convolutional and graph attention networks to predict SRIs on the basis of RNA secondary structure. SMRTnet achieves high performance across multiple experimental benchmarks, substantially outperforming existing tools. SMRTnet predictions for ten disease-associated RNA targets identified 40 hits of RNA-targeting small molecules with nanomolar-to-micromolar dissociation constants. Focusing on the MYC internal ribosome entry site, SMRTnet-predicted small molecules showed binding scores correlated closely with observed validation rates. One predicted small molecule downregulated MYC expression, inhibited proliferation and promoted apoptosis in three cancer cell lines. Thus, by eliminating the need for RNA tertiary structures, SMRTnet expands the scope of feasible RNA targets and accelerates the discovery of RNA-targeting therapeutics.

> **中文摘要：**
> 小分子可以与RNA结合以调控其命运和功能，为治疗人类疾病提供了有前景的机会。然而，目前用于预测小分子–RNA相互作用（SRI）的工具需要事先了解RNA的三级结构。本文提出了一种名为SMRTnet的深度学习方法，该方法利用多模态数据融合，将两个大型语言模型与卷积神经网络和图注意力网络相结合，根据RNA的二级结构预测SRI。SMRTnet在多个实验基准中表现优异，显著优于现有工具。针对十个与疾病相关的RNA靶点，SMRTnet预测出40种与RNA结合的小分子命中化合物，其解离常数在纳摩尔到微摩尔范围内。以MYC内部分枝点核糖体进入位点为例，SMRTnet预测的小分子其结合评分与实际验证率高度相关。其中一个预测小分子可下调MYC表达，抑制增殖并促进三种癌细胞系的凋亡。因此，通过消除对RNA三级结构的依赖，SMRTnet拓展了可行RNA靶点的范围，并加速了RNA靶向治疗药物的发现。

### 第二部分 AI 大师评价

该研究旨在突破RNA三级结构依赖的预测限制，构建了基于二级结构信息的深度学习框架SMRTnet。作者通过多模态数据融合与语言模型结合图神经网络的方法，实现了高精度预测小分子–RNA相互作用。实验结果证明其在多个基准测试中优于现有工具，并成功预测出具有生物学效应的候选小分子。该研究在RNA靶向药物开发领域具有显著创新性，但其泛化性及在复杂生理环境中的应用仍需进一步验证。

---

## 9. 利用 CHANGE-seq-BE 对碱基编辑器诱导的脱靶活性进行灵敏且无偏的全基因组分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482541)
**期刊：** Nature biotechnology
**PMID：** 41482541
**DOI：** 10.1038/s41587-025-02948-7

### 第一部分 原文与翻译

**英文原标题：** Sensitive and unbiased genome-wide profiling of base-editor-induced off-target activity using CHANGE-seq-BE.

> **英文摘要：**
> Detection of the off-target effects of base editors is important for identifying their safety risks but current methods for understanding their global activities have limitations in terms of sensitivity or bias by computationally selecting a subset of sites for experimental analysis. We present CHANGE-seq-BE, a method to assess the guide RNA-dependent off-target profile of both adenine and cytosine base editors that is simultaneously sensitive and unbiased. CHANGE-seq-BE relies on selective sequencing of base-editor-modified genomic DNA in vitro and provides comprehensive identification of genome-wide off-target mutations. We found that 98.8% of validated off-target sites were unique to ABE8e adenine base editors compared to Cas9 nuclease, suggesting substantially higher off-target activity of the former. We further applied CHANGE-seq-BE to support genotoxicity studies in an emergency investigational new drug application for customized adenine base editor treatment for a person with CD40L-deficient X-linked hyper IgM syndrome. Our results emphasize the importance of using a base-editor-specific method for identifying off-target activity.

> **中文摘要：**
> 检测碱基编辑器的脱靶效应对于识别其安全风险至关重要，但目前理解其全局活性的研究方法在灵敏度或偏倚方面存在局限性，常常通过计算方法选择部分位点进行实验分析。我们提出了 CHANGE-seq-BE 方法，用于同时灵敏且无偏地评估腺嘌呤和胞嘧啶碱基编辑器的向导 RNA 依赖性脱靶谱。CHANGE-seq-BE 依赖于对经碱基编辑器修饰的基因组 DNA 进行体外选择性测序，从而全面鉴定全基因组范围内的脱靶突变。我们发现，与 Cas9 核酸酶相比，经验证的脱靶位点中有 98.8% 为 ABE8e 腺嘌呤碱基编辑器所特有，这表明其脱靶活性显著高于 Cas9。我们进一步将 CHANGE-seq-BE 应用于一个针对 CD40L 缺陷的 X 连锁高 IgM 综合征患者的个体化腺嘌呤碱基编辑治疗紧急新药申请中的基因毒性研究。我们的研究结果强调了使用基于碱基编辑器特异性的方法来鉴定脱靶活性的重要性。

### 第二部分 AI 大师评价

该研究旨在开发一种更灵敏且无偏的碱基编辑器脱靶检测方法。通过引入 CHANGE-seq-BE，作者创新性地实现了对腺嘌呤和胞嘧啶碱基编辑器的全基因组脱靶谱全面评估。结果显示 ABE8e 的脱靶活性显著高于 Cas9，具有重要的安全性提示价值。研究不仅验证了方法的可靠性，还在真实临床应用场景中展示了其实用性，突显了其在基因编辑安全评估中的潜在推广价值。

---

## 10. 头颈部癌中与阿维鲁单抗联合放化疗疗效与耐药相关的肿瘤生态系统及微生物组特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482527)
**期刊：** Nature cancer
**PMID：** 41482527
**DOI：** 10.1038/s43018-025-01068-0

### 第一部分 原文与翻译

**英文原标题：** Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer.

> **英文摘要：**
> Immune checkpoint blockade-based multimodal therapy is widely used across oncology; yet drivers of resistance in most cancer types are not well understood. Here, we comprehensively characterized the tumor genome, microenvironment and microbiome in a phase 3 international randomized trial ( NCT02952586 ) to identify factors that shape outcomes to anti-PD-L1 avelumab plus standard-of-care chemoradiotherapy versus placebo/chemoradiotherapy in individuals with locally advanced head and neck cancer. Patients receiving avelumab whose tumors contained distinct immunologic and genetic features had superior outcomes compared to those receiving placebo. By contrast, patients with increased myeloid/neutrophil activities had worse outcomes with avelumab than those treated with placebo. Strikingly, these tumors possessed telltale intratumoral bacteria, elevated tumor-associated neutrophils, high systemic neutrophil-to-lymphocyte ratios and suppressed adaptive immunity. We define tumor ecosystems associated with benefit to chemoimmunotherapy. Our data demonstrate how intratumoral bacteria affect immune checkpoint blockade response within a randomized trial. These discoveries enhance our understanding of combination immunotherapy, provide a useful multiomic resource and identify unanticipated interactions that may guide future therapeutic strategies.

> **中文摘要：**
> 基于免疫检查点阻断的多模式治疗在肿瘤学领域广泛应用；然而，大多数癌症类型中耐药的驱动因素仍未被充分理解。在此，我们在一项国际多中心Ⅲ期随机试验（NCT02952586）中，对局部晚期头颈癌患者的肿瘤基因组、微环境及微生物组进行了全面表征，以识别影响抗PD-L1药物阿维鲁单抗联合标准放化疗与安慰剂加放化疗疗效差异的因素。接受阿维鲁单抗治疗且肿瘤具有特定免疫及遗传特征的患者，其疗效优于接受安慰剂的患者。相反，具有高髓系/中性粒细胞活性的患者在接受阿维鲁单抗治疗时的预后反而劣于安慰剂组。值得注意的是，这些肿瘤表现出具有特征性的肿瘤内细菌、升高的肿瘤相关中性粒细胞、高系统性中性粒细胞/淋巴细胞比值以及受抑制的适应性免疫反应。我们界定了与化学免疫治疗获益相关的肿瘤生态系统。我们的数据展示了肿瘤内细菌如何在随机对照研究中影响免疫检查点阻断的应答。这些发现深化了我们对联合免疫治疗机制的理解，提供了有价值的多组学资源，并揭示了潜在的相互作用，为未来治疗策略提供指导。

### 第二部分 AI 大师评价

本研究以头颈部癌为模型，基于随机III期临床试验系统解析了阿维鲁单抗联合放化疗疗效差异背后的多组学因素。研究发现肿瘤免疫基因特征与微生物组共同塑造治疗反应，其中高髓系活性和特定肿瘤内细菌与疗效降低相关。该工作首次在随机对照中揭示微生物与免疫阻断应答的交互机制，具有重要科学创新性。但研究仍受样本复杂性和因果推断局限的影响，后续验证仍需深入。

---

## 11. 一种分子胶剂阻断 RAS-MAPK 信号通路。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482526)
**期刊：** Nature cancer
**PMID：** 41482526
**DOI：** 10.1038/s43018-025-01052-8

### 第一部分 原文与翻译

**英文原标题：** A molecular glue halts RAS-MAPK signaling.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究报道了一种可作为“分子胶”的化合物，能够精确干预 RAS-MAPK 信号通路，这一通路在多种肿瘤的发生与进展中起关键作用。尽管尚无摘要可供详细解读，但从标题可推测该研究通过分子层面的新机制实现了信号传导的抑制，具备重要的药物发现与精准治疗潜力。此类‘分子胶’策略或代表调控难成药靶点的新方向，但其可逆性、安全性及适用范围仍需进一步系统验证。

---

## 12. 肿瘤细菌负荷决定头颈癌免疫治疗的结局。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482525)
**期刊：** Nature cancer
**PMID：** 41482525
**DOI：** 10.1038/s43018-025-01074-2

### 第一部分 原文与翻译

**英文原标题：** Tumor bacterial burden dictates immunotherapy fate in head and neck cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究发表于《Nature Cancer》，题目指向肿瘤内细菌负荷与头颈癌免疫治疗反应之间的关联。虽然未提供摘要，但从题目可推测，研究可能探讨了肿瘤微生物组在免疫治疗疗效与耐药性中的关键作用，尤其是细菌量对免疫应答的调控影响。此类研究有助于揭示肿瘤免疫环境的新决定因素，并为个体化免疫疗法制定提供新思路。然而，若缺乏临床样本规模和机制验证，结论的普适性仍需谨慎评估。

---

## 13. MEK-RAF分子胶IK-595在具有RAS/MAPK通路改变的肿瘤中表现出强效抗肿瘤活性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482524)
**期刊：** Nature cancer
**PMID：** 41482524
**DOI：** 10.1038/s43018-025-01081-3

### 第一部分 原文与翻译

**英文原标题：** The MEK-RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers.

> **英文摘要：**
> MAPK pathway alterations are the most common oncogenic drivers. Among the approved therapies targeting this pathway are RAS, MEK and RAF inhibitors. However, therapeutic resistance and toxicities have limited their clinical success. Here, to overcome these liabilities, we developed IK-595, a potent MEK-RAF molecular glue. IK-595 traps MEK in an inactive complex with all RAF isoforms. In addition, IK-595 precludes CRAF-mediated MEK reactivation and ARAF heterodimerization, allowing for prolonged target engagement and durable MAPK pathway inhibition. This translates into superior antitumor activity across a wide range of cancer model indications harboring MAPK pathway alterations. A key advantage of IK-595 is its ability to achieve transient high plasma exposure affording a larger therapeutic window. The unique mechanism of action and improved tolerability positions IK-595 as an ideal combination partner. IK-595 is an MEK-RAF molecular glue that prolongs pathway inhibition while providing a broader therapeutic window as monotherapy and in combination.

> **中文摘要：**
> MAPK通路的改变是最常见的致癌驱动因素之一。已获批准的靶向该通路的疗法包括RAS、MEK和RAF抑制剂。然而，治疗耐药性和毒性限制了它们的临床成功率。为克服这些缺陷，我们开发了IK-595，这是一种强效的MEK-RAF分子胶。IK-595可将MEK捕获于与所有RAF同工型组成的失活复合物中。此外，IK-595可阻止CRAF介导的MEK再活化及ARAF异源二聚化，从而实现持久的靶点结合与持续的MAPK通路抑制。这种机制在广泛的、携带MAPK通路改变的癌症模型中转化为更优越的抗肿瘤活性。IK-595的一个关键优势在于其能够实现瞬时高血浆暴露，从而获得更大的治疗窗口。其独特的作用机制和改进的耐受性使IK-595成为理想的联合用药伙伴。IK-595是一种MEK-RAF分子胶，可在单药及联合治疗中延长通路抑制并提供更广的治疗窗口。

### 第二部分 AI 大师评价

本研究旨在开发一种新型的MEK-RAF分子胶IK-595，以克服RAS/MAPK通路靶向治疗中的耐药与毒性问题。通过抑制MEK与各RAF同工型的活性相互作用，IK-595实现了持续的MAPK通路抑制与广谱抗肿瘤效应。研究突出了其短暂高暴露带来的宽治疗窗及优异的靶点结合持久性。该成果在机制创新性和耐受性改善方面具有重要意义，但仍需进一步验证其在临床环境中的疗效与安全性。

---

## 14. 肿瘤内细菌具有免疫抑制作用并促进头颈部鳞状细胞癌的免疫治疗耐受性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482523)
**期刊：** Nature cancer
**PMID：** 41482523
**DOI：** 10.1038/s43018-025-01067-1

### 第一部分 原文与翻译

**英文原标题：** Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma.

> **英文摘要：**
> Despite the promise of immune checkpoint blockade (ICB) in head and neck squamous cell carcinoma (HNSCC), mediators of response are poorly understood. To address this, here we analyzed oropharyngeal HNSCCs treated with neoadjuvant durvalumab (anti-PDL1) alone or in combination with tremelimumab (anti-CTLA4) from the CIAO clinical trial ( NCT03144778 ). We found that only the total abundance of intratumoral bacteria predicted ICB response, which was validated in multiple independent cohorts. High intratumoral bacteria abundance was associated with an immunosuppressive tumor microenvironment, characterized by an accumulation of neutrophils coupled with depletion of T cells and other adaptive immune cells. Experimental elevation or reduction in intratumoral bacteria abundance in orthotopic models of HNSCC in female mice recapitulated immunological associations observed in participant tumors. Increasing intratumoral bacteria abundance was sufficient to induce resistance to anti-PDL1 ICB, irrespective of bacterial species tested. Together, these findings demonstrate that high intratumoral bacteria abundance is a key suppressor of antitumor immunity and promotes immunotherapy resistance.

> **中文摘要：**
> 尽管免疫检查点阻断（ICB）在头颈部鳞状细胞癌（HNSCC）中显示出良好前景，但其反应的介导因素仍知之甚少。为了解决这一问题，本研究分析了来自CIAO临床试验（NCT03144778）的口咽部HNSCC患者，这些患者接受了新辅助度伐利尤单抗（抗PD-L1）单药治疗或与特瑞美单抗（抗CTLA4）联合治疗。我们发现，只有肿瘤内细菌的总体丰度能够预测ICB的反应性，这一结果在多个独立队列中得到了验证。高丰度的肿瘤内细菌与免疫抑制性肿瘤微环境相关，其特征为中性粒细胞积聚并伴随T细胞及其他适应性免疫细胞的减少。在雌性小鼠头颈部鳞癌的原位模型中，通过实验性地增加或减少肿瘤内细菌丰度，可重现受试者肿瘤中观察到的免疫学关联。无论测试的细菌种类如何，仅提高肿瘤内细菌丰度就足以诱导抗PD-L1 ICB耐受性。综上所述，这些发现表明，高水平肿瘤内细菌丰度是抗肿瘤免疫的重要抑制因素，并促进了免疫治疗的耐受性。

### 第二部分 AI 大师评价

本研究旨在阐明肿瘤内细菌在头颈部鳞状细胞癌免疫检查点治疗反应中的作用机制。作者通过临床试验样本与动物模型的系统分析，揭示了肿瘤内细菌丰度可预测免疫治疗反应，并与免疫抑制性微环境密切相关。实验结果明确说明，单纯增加细菌负荷即可诱导抗PD-L1治疗耐受。该研究创新性地将肿瘤微生物生态与免疫治疗疗效直接联系，为提升免疫疗法效果提供了潜在靶点，但仍需进一步探讨细菌种类及干预策略的可行性。

---

## 15. 源自——的蛋氨酸促进胃癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482458)
**期刊：** Gut
**PMID：** 41482458
**DOI：** 10.1136/gutjnl-2025-336966

### 第一部分 原文与翻译

**英文原标题：** -derived methionine promotes gastric cancer progression.

> **英文摘要：**
> BACKGROUND: has been linked with an increasing risk of gastric cancer (GC) and recognised as a signature for GC screening.
> 
> OBJECTIVE: To investigate the promotional effect of  in terms of its metabolic interactions with the host.
> 
> DESIGN: We used the functional profiles of shotgun metagenomic sequencing from stools to detect bioactive molecules relevant to . In vivo and in vitro experiments were used to validate the facilitation of  to GC progression.  clinical strains were isolated and cultivated from cancerous tissues to verify its promotion of GC via methionine production.  mutant strains were constructed to confirm the critical role of  in methionine biosynthesis.
> 
> RESULTS: We verified  facilitated GC progression in vivo and in vitro. Our functional analysis of metagenomes revealed a significant enrichment of bacterial methionine biosynthesis pathways in GC patients with high  abundance. Methionine, identified here as one of the primary microbial metabolites derived from  contributed to GC progression in humans and mice.  strains from cancerous tissues were found to promote GC via methionine production. We further observed a higher abundance and prevalence of  gene in cancer stool metagenomes. By constructing an  mutant strain, we confirmed the critical role of  in methionine biosynthesis.
> 
> CONCLUSION: Our results elucidate the role of -derived methionine in GC progression, shedding light on intricate metabolic interplay between  and host.

> **中文摘要：**
> 背景：——与胃癌（GC）风险增加有关，并被认为是GC筛查的一个标志特征。
> 
> 目的：探讨——通过其与宿主的代谢相互作用对GC的促进作用。
> 
> 设计：我们利用粪便的宏基因组鸟枪法测序功能谱，检测与——相关的生物活性分子。通过体内和体外实验验证——对GC进展的促进作用。从癌组织中分离并培养——临床菌株，以确认其通过蛋氨酸生成促进GC的能力。构建——突变株以确认其在蛋氨酸生物合成中的关键作用。
> 
> 结果：我们在体内和体外实验中均验证了——可促进GC的进展。宏基因组功能分析显示，在——丰度较高的GC患者中，细菌蛋氨酸生物合成通路显著富集。蛋氨酸作为本研究鉴定的主要微生物代谢产物之一，源自——的代谢产物，促进了人类和小鼠的GC进展。从癌组织中分离的——菌株可通过蛋氨酸生成促进GC。我们进一步观察到癌症粪便宏基因组中——基因的丰度和普遍性升高。通过构建——突变株，进一步确认了其在蛋氨酸生物合成中的关键功能。
> 
> 结论：我们的结果揭示了源自——的蛋氨酸在GC进展中的作用，阐明了——与宿主之间复杂的代谢互作机制。

### 第二部分 AI 大师评价

该研究以宿主-微生物代谢互作为切入点，探讨了来自特定细菌的蛋氨酸如何促进胃癌进展。研究通过结合宏基因组分析与体内外实验，揭示了微生物蛋氨酸合成通路在胃癌患者中的富集及其致病作用。创新性地将肿瘤代谢依赖与微生态代谢产物联系起来，为理解菌群介导的肿瘤代谢通路提供了新视角。其局限在于具体致病菌种可能未完全揭示，需进一步阐明宿主信号通路的下游机制。

---

## 16. CD48 是肝细胞癌肿瘤相关巨噬细胞上的一种新型免疫检查点。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41482455)
**期刊：** Gut
**PMID：** 41482455
**DOI：** 10.1136/gutjnl-2025-336744

### 第一部分 原文与翻译

**英文原标题：** CD48 is a novel immune checkpoint on tumour-associated macrophages in hepatocellular carcinoma.

> **英文摘要：**
> BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite promising immunotherapy, response rates remain suboptimal. Tumour-associated macrophages (TAMs) constitute a pivotal component of the immunosuppressive HCC microenvironment, yet TAM heterogeneity and contributions to tumour progression and immunotherapy resistance remain poorly defined.
> 
> OBJECTIVE: To identify and characterise critical TAM subsets in HCC and evaluate their potential as therapeutic targets.
> 
> DESIGN: Integrated multiomics analysis of hepatocellular carcinoma (HCC) clinical specimens was performed and validated across independent cohorts. Single-cell RNA sequencing identified tumour-associated macrophage (TAM) subpopulations. Functional characterisation employed whole-body and macrophage-specific CD48 knockout mice, adoptive transfer experiments and co-culture systems. Mechanistic studies used immunoprecipitation-mass spectrometry, immunofluorescence colocalisation and pathway analysis. Therapeutic efficacy was evaluated using anti-CD48 monotherapy and combination with anti-programmed cell death protein 1 (PD1) in orthotopic HCC models.
> 
> RESULTS: CD48 TAMs were identified associating with accelerated tumour progression, immunotherapy resistance and poor clinical outcomes. These TAMs exhibited protumorous phenotypes, driving immunosuppression and promoting extracellular matrix remodelling. Genetic CD48 ablation attenuated HCC progression while promoting CD8 T-cell function. Adoptive transfer of CD48-deficient macrophages validated tumour-suppressive effects. Mechanistically, matrix metalloproteinase-14 (MMP14) was identified as a novel cis-interacting partner for CD48, functioning independently of the canonical CD48-CD244 axis. This interaction activated RAP1 GTPase, triggering Yes-associated protein (YAP) nuclear translocation and YAP-signal transducer and activator of transcription 3 (STAT3) complex formation to upregulate immunosuppressive genes. Anti-CD48 antibodies effectively inhibited tumour progression and demonstrated synergistic effects with anti-PD1 therapy.
> 
> CONCLUSION: CD48 represents a novel immune checkpoint on TAMs critical for HCC progression and immunotherapy resistance. Targeting CD48 may overcome immunosuppression and increase therapeutic efficacy in HCC.

> **中文摘要：**
> 背景：肝细胞癌（HCC）是导致癌症死亡的主要原因之一，治疗手段有限。尽管免疫治疗前景可期，但应答率仍不理想。肿瘤相关巨噬细胞（TAMs）是免疫抑制性HCC微环境的重要组成部分，但其异质性及其在肿瘤进展和免疫治疗耐受中的作用尚不清楚。
> 
> 目的：鉴定并表征HCC中关键的TAM亚群，并评估其作为治疗靶点的潜力。
> 
> 设计：对肝细胞癌（HCC）临床样本进行整合多组学分析，并在独立队列中进行了验证。单细胞RNA测序鉴定了肿瘤相关巨噬细胞（TAMs）亚群。功能性研究采用全身性及巨噬细胞特异性CD48基因敲除小鼠、接受性转移实验及共培养系统。机制研究使用免疫共沉淀-质谱分析、免疫荧光共定位及信号通路分析。治疗效果通过在原位HCC模型中评估抗CD48单药治疗及与抗程序性细胞死亡蛋白1（PD1）的联合治疗。
> 
> 结果：鉴定出CD48阳性TAM与肿瘤进展加速、免疫治疗耐受及不良临床结局相关。这些TAM表现出促肿瘤表型，驱动免疫抑制并促进细胞外基质重塑。CD48的基因剔除减缓了HCC进展并增强了CD8 T细胞功能。转移CD48缺失的巨噬细胞验证了其抑瘤作用。从机制上看，基质金属蛋白酶-14（MMP14）被鉴定为CD48的新型顺式相互作用伙伴，其功能独立于经典的CD48-CD244轴。该相互作用激活RAP1 GTP酶，诱导Yes相关蛋白（YAP）核转位，并形成YAP-信号转导及转录激活因子3（STAT3）复合物，从而上调免疫抑制基因。抗CD48抗体可有效抑制肿瘤进展，并与抗PD1治疗表现出协同效应。
> 
> 结论：CD48是TAM上的一种新型免疫检查点，对HCC进展和免疫治疗耐受具有关键作用。靶向CD48可能克服免疫抑制并提高HCC治疗效果。

### 第二部分 AI 大师评价

该研究系统揭示了CD48在肝细胞癌肿瘤相关巨噬细胞中的免疫调控新机制，展示了多组学结合单细胞测序的强大解析能力。作者发现CD48不仅促进肿瘤进展且介导免疫治疗耐受，并确立其与MMP14及YAP-STAT3通路的关键联系。动物实验验证了靶向CD48的治疗潜力并显示与抗PD1疗法的协同效应。研究创新在于首次定义了CD48作为TAM免疫检查点的功能，为HCC免疫治疗提供了新靶点，但仍需临床层面进一步验证其安全性与可行性。

---

## 17. 发热温度通过促进异常甲型流感病毒RNA合成激活先天免疫反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481744)
**期刊：** Science advances
**PMID：** 41481744
**DOI：** 10.1126/sciadv.aeb2700

### 第一部分 原文与翻译

**英文原标题：** Febrile temperature activates the innate immune response by promoting aberrant influenza A virus RNA synthesis.

> **英文摘要：**
> Fever during influenza A virus (IAV) infection is triggered by the innate immune response. Various factors contribute to this response, including IAV mini viral RNAs (mvRNA), which trigger RIG-I signaling when their replication and transcription are dysregulated by template loops (t-loops). It is presently not well understood whether the fever response to IAV infection affects subsequent viral replication and innate immune activation. Here, we show that IAV infection at temperatures that simulate fever leads to increased antiviral signaling in H1N1 and H3N2 infections. Mathematical modeling and experimental analyses reveal that differential IAV nucleoprotein and RNA polymerase production increase mvRNA and interferon production. Moreover, at the higher infection temperature, mvRNAs with dysregulating t-loops contribute most to the innate immune activation. We propose that fever during IAV infection can establish a positive feedback loop in which elevated aberrant RNA synthesis and innate immune activation can contribute to the dysregulation of cytokine production.

> **中文摘要：**
> 在甲型流感病毒（IAV）感染过程中，发热是由先天免疫反应触发的。多种因素参与了这一反应，包括IAV的小病毒RNA（mvRNA），当其复制和转录受到模板环结构（t-loops）失调调控时，会激活RIG-I信号通路。目前尚不清楚IAV感染引发的发热反应是否影响随后的病毒复制和先天免疫激活。在本研究中，我们显示，模拟发热温度的IAV感染会增强H1N1和H3N2感染中的抗病毒信号通路。数学建模与实验分析表明，不同水平的IAV核蛋白和RNA聚合酶产量会增加mvRNA和干扰素的生成。此外，在较高感染温度下，具有失调t-loops的mvRNA对先天免疫激活的贡献最大。我们提出，在IAV感染时，发热可能建立一个正反馈循环，其中升高的异常RNA合成和先天免疫激活可进一步导致细胞因子生成的失调。

### 第二部分 AI 大师评价

该研究旨在揭示发热温度对甲型流感病毒感染中先天免疫反应的作用机制。研究结合数学建模与实验分析，发现发热温度下异常RNA合成增强了RIG-I介导的抗病毒信号和干扰素生成。结果表明，发热可通过促进异常mvRNA形成及其t-loop调控，建立免疫激活与RNA异常合成的正反馈环。这一发现为理解发热的免疫调节机制提供了新见解，但仍需在人体系统中进一步验证其生理相关性。

---

## 18. FSP1和组蛋白去乙酰化酶抑制癌症持存细胞的铁死亡

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481741)
**期刊：** Science advances
**PMID：** 41481741
**DOI：** 10.1126/sciadv.aea8771

### 第一部分 原文与翻译

**英文原标题：** FSP1 and histone deacetylases suppress cancer persister cell ferroptosis.

> **英文摘要：**
> Cancer persister cells which survive oncogene targeted therapies are sensitized to ferroptosis, but mechanistic understanding of this vulnerability remains limited. Here, we found that while levels of iron, glutathione, and various ferroptosis-suppressing enzymes vary among persister cell types, ferroptosis suppressor protein 1 (FSP1) is down-regulated in multiple persister cell types, and persister cells which survive glutathione peroxidase 4 (GPX4) inhibition rely on residual FSP1 to survive. Furthermore, persister cells which survive GPX4 inhibition down-regulate oxidative phosphorylation, a key source of mitochondrial reactive oxygen species which are required for persister cell ferroptosis. We also found that persister cell treatment with histone deacetylase inhibitors induces reactive oxygen species and sensitizes multiple persister cell types to GPX4 inhibition. Together, these findings reveal that FSP1 and histone deacetylases suppress persister cell ferroptosis.

> **中文摘要：**
> 能够在癌基因靶向治疗后存活的癌症持存细胞对铁死亡敏感，但对于这种脆弱性的机制性理解仍然有限。在本研究中，我们发现，虽然不同类型的持存细胞中铁、谷胱甘肽以及多种抑制铁死亡的酶水平存在差异，但铁死亡抑制蛋白1（FSP1）在多种持存细胞类型中下调，而能够在谷胱甘肽过氧化物酶4（GPX4）抑制下存活的持存细胞依赖残余的FSP1维持生存。此外，能够在GPX4抑制下存活的持存细胞下调了氧化磷酸化，而氧化磷酸化是线粒体活性氧的重要来源，而该活性氧对于持存细胞铁死亡是必需的。我们还发现，用组蛋白去乙酰化酶抑制剂处理持存细胞可诱导活性氧产生，并使多种持存细胞类型对GPX4抑制更加敏感。总体而言，这些发现揭示了FSP1和组蛋白去乙酰化酶共同抑制持存细胞铁死亡的机制。

### 第二部分 AI 大师评价

本研究探讨了癌症持存细胞在靶向治疗后的铁死亡易感性及其调控机制。通过系统比较不同持存细胞类型的代谢特征，作者发现FSP1的下调是铁死亡敏感性的关键因素，而氧化磷酸化降低可限制铁死亡反应。同时，组蛋白去乙酰化酶抑制剂通过诱导活性氧产生进一步增强了铁死亡敏感性。该研究揭示了FSP1与表观遗传调控在持存细胞生存中的协同作用，具有重要的治疗启示，但仍需在体内模型和临床相关性方面进一步验证。

---

## 19. 针对难治性重症肌无力的BCMA/CD19 CAR T细胞治疗：疾病复发的蛋白质组学特征与单细胞转录组学分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481736)
**期刊：** Science advances
**PMID：** 41481736
**DOI：** 10.1126/sciadv.aeb6424

### 第一部分 原文与翻译

**英文原标题：** BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

> **英文摘要：**
> Myasthenia gravis (MG) is an autoimmune disorder characterized by B cell dysfunction. Here, we designed B cell maturation antigen (BCMA)/CD19 chimeric antigen receptor T cell (CAR T cell) therapy for six refractory MGs, demonstrating favorable safety with grade 1 cytokine release syndrome observed. CAR T cell expansion induced profound B cell depletion, a sustained reduction in acetylcholine receptor (AChR) antibody titers, and symptom improvement. Five patients achieved drug-free remission with minimal manifestations by month 6, persisting through the 12-month follow-up despite B cell reconstitution. Reconstituted B cells showed naïve predominance with diminished AChR specificity and functional capacities. Olink proteomics revealed up-regulation of anti-inflammatory factors, along with down-regulation of proinflammatory molecules. Single-cell sequencing revealed that age-associated B cells (ABCs) were up-regulated in a relapsed patient, and differential gene analysis indicated that Fc receptor-like 5 (FCRL5) expression was elevated in ABCs, whereas CAR T cell responders exhibited a down-regulated trend. Notably, similar ABC expansion and FCRL5 up-regulation occurred in rituximab-relapsed patients. Our findings support BCMA/CD19 CAR T cell therapy as feasible, tolerable, and effective in MG, identifying FCRL5 as a previously unidentified target in relapse.

> **中文摘要：**
> 重症肌无力（MG）是一种以B细胞功能障碍为特征的自身免疫性疾病。本研究设计了针对六例难治性重症肌无力患者的B细胞成熟抗原（BCMA）/CD19嵌合抗原受体T细胞（CAR T细胞）治疗，结果显示该疗法具有良好的安全性，仅观察到1级细胞因子释放综合征。CAR T细胞扩增诱导了显著的B细胞清除、乙酰胆碱受体（AChR）抗体滴度的持续下降及症状改善。到第6个月时，五名患者在无需用药的情况下达到最轻症表现的缓解状态，并在B细胞重建后于12个月的随访中保持稳定。重建的B细胞以初始型为主，且AChR特异性与功能能力均减弱。Olink蛋白质组学分析显示抗炎因子上调，而促炎分子下调。单细胞测序发现，在一名复发患者中，年龄相关B细胞（ABCs）显著上调，且差异基因分析指出Fc受体样5（FCRL5）在ABCs中表达升高，而CAR T治疗应答者呈现下调趋势。值得注意的是，在利妥昔单抗复发患者中也观察到类似的ABCs扩增及FCRL5上调。本研究结果支持BCMA/CD19 CAR T细胞治疗在MG中的可行性、耐受性与疗效，并识别出FCRL5作为复发中一个此前未被发现的重要靶点。

### 第二部分 AI 大师评价

该研究首次在难治性重症肌无力中应用BCMA/CD19双靶向CAR T细胞疗法，并通过多组学手段揭示其分子机制。结果显示疗法具有良好的安全性与显著的临床缓解效果，同时揭示了B细胞重建后的免疫图谱改变。蛋白质组与单细胞转录组数据揭示FCRL5在复发中的潜在作用，为未来再发机制研究与靶向治疗提供了新方向。尽管样本量有限，但研究在自身免疫性疾病CAR T应用领域具有突破性意义。

---

## 20. 天然MHC I肽加载复合物中转运蛋白-分子伴侣耦合的结构原理

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481733)
**期刊：** Science advances
**PMID：** 41481733
**DOI：** 10.1126/sciadv.aea7735

### 第一部分 原文与翻译

**英文原标题：** Architectural principles of transporter-chaperone coupling within the native MHC I peptide-loading complex.

> **英文摘要：**
> Adaptive immunity depends on major histocompatibility complex class I (MHC I) presentation of peptides, a process orchestrated by the peptide-loading complex (PLC) in the endoplasmic reticulum (ER). The PLC ensures precise peptide selection and loading and is a major target of viral immune evasion, notably by human cytomegalovirus (HCMV). Here, we report the 2.59- to 2.88-Å cryo-electron microscopy structure of native human PLC bound to the HCMV immune evasin US6. US6 inhibits the transporter associated with antigen processing 1/2 (TAP1/2) by laterally attaching its transmembrane helix to TAP2 using a disulfide-rich domain to mimic a translocating peptide. This domain blocks the ER-lumenal exit and locks TAP in an outward-facing conformation with closed nucleotide-binding domains and asymmetric adenosine 5'-triphosphate/adenosine 5'-diphosphate occlusion. The structure also reveals how TAP's amino-terminal transmembrane domains scaffold the MHC I chaperone tapasin. These findings elucidate the mechanism of US6-mediated immune evasion and highlight potential targets for therapeutic modulation of immune presentation in infection and cancer.

> **中文摘要：**
> 适应性免疫依赖于主要组织相容性复合体I类（MHC I）对肽的呈递，这一过程由内质网（ER）中的肽加载复合物（PLC）精确协调。PLC确保肽的精确筛选与装载，并且是病毒免疫逃逸的重要靶点，尤其是人巨细胞病毒（HCMV）。本研究报道了与HCMV免疫逃逸蛋白US6结合的天然人PLC的2.59至2.88埃冷冻电子显微结构。US6通过利用一个富含二硫键的结构域来模拟转运肽，使其跨膜螺旋侧向结合于TAP2，从而抑制与抗原加工相关的转运蛋白1/2（TAP1/2）。该结构域阻断了ER腔面的出口，并将TAP锁定在外向开放构象中，同时其核苷酸结合结构域关闭，腺苷5'-三磷酸/腺苷5'-二磷酸被不对称地封闭。结构还揭示了TAP氨基端跨膜结构域如何为MHC I伴侣蛋白tapasin提供支架。这些发现阐明了US6介导的免疫逃逸机制，并指出了感染与癌症中免疫呈递治疗调控的潜在靶点。

### 第二部分 AI 大师评价

该研究利用高分辨率冷冻电镜解析了天然MHC I肽加载复合物与HCMV免疫逃逸因子US6结合的结构，揭示了US6通过模拟转运肽并锁定TAP外向开放构象实现免疫抑制的分子机制。作者进一步阐明了TAP的跨膜结构域如何支撑tapasin，丰富了对抗原加工系统空间构架的理解。该工作在揭示病毒免疫逃逸策略与抗原呈递调控原理上具有重要创新意义。尽管研究提供了关键的静态结构信息，但动态调控过程仍有待进一步探索。

---

## 21. DMTF1 上调通过 SWI/SNF–E2F 轴拯救端粒功能障碍神经干细胞的增殖缺陷

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481722)
**期刊：** Science advances
**PMID：** 41481722
**DOI：** 10.1126/sciadv.ady5905

### 第一部分 原文与翻译

**英文原标题：** DMTF1 up-regulation rescues proliferation defect of telomere dysfunctional neural stem cells via the SWI/SNF-E2F axis.

> **英文摘要：**
> Impaired neural stem cell (NSC) proliferation/activation is associated with brain aging, but the underlying mechanisms remain poorly understood. Here, we unexpectedly find that DMTF1, a transcription factor that regulates the Arf/p53 axis in cancer, is down-regulated in the NSCs of a premature aging model driven by telomerase deficiency. DMTF1 up-regulation was able to rescue the impaired proliferation of telomere dysfunctional NSCs. Mechanistically, DMTF1 regulates the transcription of Arid2 and Ss18 genes, two subunits of the SWI/SNF complexes that mediate H3K27ac at E2F gene promoters to promote NSC proliferation. Accordingly, Arid2 or Ss18 depletion phenocopies DMTF1 loss in reducing H3K27ac levels, expression of E2F target genes, and NSC proliferation. Thus, our study has identified DMTF1 as a potential therapeutic target to reverse the proliferation defect of aged NSC that is modeled by telomere attrition and unearthed a distinct genetic program controlled by DMTF1 in NSC.

> **中文摘要：**
> 神经干细胞（NSC）的增殖和激活受损与脑老化相关，但其潜在机制仍不甚明了。在本研究中，我们意外发现，在由端粒酶缺陷驱动的早衰模型中，DMTF1——一种在癌症中调控 Arf/p53 轴的转录因子——在 NSC 中呈下调状态。DMTF1 的上调能够恢复端粒功能障碍 NSC 的受损增殖能力。从机制上看，DMTF1 调控 Arid2 和 Ss18 基因的转录，这两个基因编码 SWI/SNF 复合物的亚基，后者在 E2F 基因启动子上介导 H3K27ac 修饰，从而促进 NSC 的增殖。相应地，Arid2 或 Ss18 的缺失会模拟 DMTF1 缺失的效应，导致 H3K27ac 水平下降、E2F 靶基因表达减少以及 NSC 增殖受抑。因此，我们的研究确认 DMTF1 是一种潜在的治疗靶点，可用于逆转由端粒缩短模型化的老化 NSC 增殖缺陷，并揭示了 DMTF1 在 NSC 中调控的独特遗传程序。

### 第二部分 AI 大师评价

该研究旨在揭示端粒功能障碍引起的神经干细胞增殖缺陷的分子机制。通过在早衰模型中发现 DMTF1 下调并验证其上调可恢复增殖，研究者明确了 DMTF1 在调控 SWI/SNF 复合物亚基 Arid2 和 Ss18 及下游 E2F 目标基因中的关键作用。该工作创新性地建立了 DMTF1–SWI/SNF–E2F 轴与神经干细胞老化相关的分子联系，为延缓或逆转神经老化提供了潜在靶点。研究的局限在于尚需在体内模型中进一步验证其可转化性及长期效应。

---

## 22. PARP1 通过 p38 相关的反馈调控稳定 FOXN3 从而抑制肺纤维化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481720)
**期刊：** Science advances
**PMID：** 41481720
**DOI：** 10.1126/sciadv.ady1681

### 第一部分 原文与翻译

**英文原标题：** PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation.

> **英文摘要：**
> The transcriptional repressor forkhead box N3 (FOXN3) has been reported to suppress pulmonary fibrosis by inhibiting Smad transcriptional activity. However, FOXN3 becomes unstable in response to profibrotic stimuli. This study identifies poly(ADP-ribose) polymerase-1 (PARP1) as a stabilizing partner of FOXN3, preventing its degradation by blocking p38-mediated phosphorylation. Lung-specific knockout (KO) of PARP1 promotes the development of pulmonary fibrosis by reducing the abundance of FOXN3. Conditional overexpression of FOXN3 notably mitigates pulmonary fibrosis resulting from PARP1 KO by impeding Smad signaling, underscoring the critical role of the PARP1-FOXN3 axis in pulmonary fibrosis. Mechanistically, p38 is a Smad response gene that is transcriptionally repressed by the PARP1/FOXN3 complex. The disruption of PARP1 or FOXN3 increases p38 expression, which in turn facilitates FOXN3 degradation through a feedback mechanism. This cascade activates Smad signaling, leading to a profibrotic response and myofibroblast activation. Notably, levels of PARP1 and FOXN3 are significantly reduced in patients with pulmonary fibrosis, highlighting PARP1's crucial role in suppressing the disease by regulating FOXN3-mediated Smad signaling.

> **中文摘要：**
> 转录抑制因子 forkhead box N3（FOXN3）已被报道可通过抑制 Smad 转录活性来抑制肺纤维化。然而，FOXN3 在促纤维化刺激下变得不稳定。本研究确定了多(ADP-核糖)聚合酶-1（PARP1）是 FOXN3 的稳定性伙伴，通过阻断 p38 介导的磷酸化来防止其降解。肺特异性敲除（KO）PARP1 会通过降低 FOXN3 的丰度而促进肺纤维化的发展。条件性过表达 FOXN3 可显著减轻由 PARP1 缺失引起的肺纤维化，通过阻断 Smad 信号通路，强调了 PARP1-FOXN3 轴在肺纤维化中的关键作用。从机制上看，p38 是一个受 Smad 调控的反应基因，其转录受到 PARP1/FOXN3 复合物的抑制。当 PARP1 或 FOXN3 功能受损时，p38 的表达上升，反过来又通过反馈机制促进 FOXN3 的降解。该级联反应激活 Smad 信号，导致促纤维化反应及肌成纤维细胞活化。值得注意的是，在肺纤维化患者中，PARP1 和 FOXN3 的水平显著下降，突出了 PARP1 通过调控 FOXN3 介导的 Smad 信号在抑制该疾病中的关键作用。

### 第二部分 AI 大师评价

本研究揭示了 PARP1 在维持 FOXN3 稳定性中的重要作用，并阐明了其通过 p38 相关反馈环调控 Smad 信号以抑制肺纤维化的机制。作者采用了肺特异性敲除与条件性过表达模型，系统验证了 PARP1-FOXN3 轴的生理功能。研究创新性地揭示了 p38 既作为 Smad 靶基因又参与 FOXN3 降解的双向调控机制，构成新的纤维化反馈环。尽管该研究主要基于小鼠模型，仍为临床治疗提供了潜在的分子靶点。

---

## 23. 利用DNA支架纳米颗粒双受体靶向I型树突状细胞以增强STING介导的抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481710)
**期刊：** Science advances
**PMID：** 41481710
**DOI：** 10.1126/sciadv.aeb0452

### 第一部分 原文与翻译

**英文原标题：** Dual-receptor targeting of type I dendritic cells with DNA-scaffolded nanoparticles enhances STING-licensed antitumor immunity.

> **英文摘要：**
> Activating the stimulator of interferon genes (STING) pathway in conventional type I dendritic cells (cDC1s) is crucial for inhibiting solid tumor metastasis. A major hurdle is the cell type-specific delivery of immune agonists. To overcome this, we created a DNA-scaffolded poly(lactic--glycolic acid) nanoparticle platform for precisely loading antibodies targeting cDC1 receptors, specifically DEC205 and Clec9A. Optimizing these targeting ligands revealed a 1:1 ratio as ideal for preferentially targeting splenic cDC1s in vivo. When the STING agonist MSA-2 was delivered via this platform, termed programmable and ratiometrically-engineered immunomodulatory nanoparticle (PRIME NP), its immunostimulatory activity significantly increased. In CT26 tumor-bearing mice, PRIME NP treatment triggered robust proinflammatory signaling and activated both innate and adaptive immune responses, leading to potent CD8 T cell-driven tumor regression and long-term survival in preclinical models. This work provides a framework for designing actively targeted particles and emphasizes DNA-scaffolded nanoparticles as an effective strategy to enhance the STING-cDC1 pathway for solid tumor treatment.

> **中文摘要：**
> 在常规I型树突状细胞（cDC1）中激活干扰素基因刺激因子（STING）通路，对于抑制实体瘤转移至关重要。一个主要障碍是如何实现特定细胞类型的免疫激动剂递送。为克服这一问题，我们构建了一种以DNA为支架的聚乳酸-羟基乙酸（PLGA）纳米颗粒平台，用于精准加载靶向cDC1受体的抗体，特别是DEC205和Clec9A。通过优化这些靶向配体，确定1:1的比例是体内优先靶向脾脏cDC1的理想方案。当STING激动剂MSA-2通过该平台递送时，其免疫刺激活性显著增强。该平台被称为可编程比例工程免疫调节纳米颗粒（PRIME NP）。在CT26肿瘤荷瘤小鼠模型中，PRIME NP治疗触发了强烈的促炎信号，激活了先天性和适应性免疫反应，最终导致CD8 T细胞介导的肿瘤显著回归，并在临床前模型中获得长期生存。本研究为设计主动靶向的纳米颗粒提供了框架，并强调DNA支架纳米颗粒作为一种增强STING-cDC1通路以治疗实体肿瘤的有效策略。

### 第二部分 AI 大师评价

本研究的目标是通过DNA支架纳米颗粒精确地靶向I型树突状细胞，实现STING通路的高效激活，以增强抗肿瘤免疫。作者创新性地设计了可调控配体比例的PRIME NP平台，通过同时靶向DEC205和Clec9A，实现了特异性免疫激动剂递送。该方法在动物模型中显著增强了CD8 T细胞响应并抑制肿瘤生长，显示出较强的临床潜力。其创新性体现在DNA支架的可编程化构建与比例工程策略上，但未来仍需评估其在复杂组织环境中的安全性与可转化性。

---

## 24. IDH2 和 SRSF2 突变通过协同的基因内表观遗传失调导致关键转录调控因子的错误剪接。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481703)
**期刊：** Science advances
**PMID：** 41481703
**DOI：** 10.1126/sciadv.adu8292

### 第一部分 原文与翻译

**英文原标题：** Synergistic intragenic epigenetic deregulation by IDH2 and SRSF2 mutations causes mis-splicing of key transcriptional regulators.

> **英文摘要：**
> Genes affecting DNA methylation (DNAme) are frequently comutated with splicing factors in acute myeloid leukemia (AML) and associate with more aggressive phenotypes. To elucidate the underlying molecular mechanisms, we deeply profiled wild-type and  single- or double-mutant AMLs. We find a unique set of mis-spliced genes and differentially methylated CpGs in double mutants. Mis-spliced exons are enriched in CCNG splicing enhancers and in the corresponding DNAme changes. Using a machine learning model, we can accurately predict exon inclusion levels from proximal CpGs. These CpGs are more likely to overlap footprints of RNA binding and chromatin-modifying complexes but not transcription factors. We also report unique gene expression profiles associated with each genotype; however, the differentially expressed genes do not overlap with mis-spliced transcripts. Instead, the mis-spliced genes encode for proteins that interact with the complexes regulating these differentially expressed genes. Thus, aberrant DNAme and splicing lead to the mis-splicing of key regulatory complexes, resulting in the aberrant gene expression profiles characteristic of these AMLs.

> **中文摘要：**
> 影响 DNA 甲基化（DNAme）的基因在急性髓性白血病（AML）中常与剪接因子共突变，并与更具侵袭性的表型相关。为阐明其潜在的分子机制，我们对野生型以及单突变或双突变 AML 进行了深入分析。我们发现双突变中存在一组独特的错误剪接基因和差异甲基化的 CpG 位点。错误剪接的外显子富集于 CCNG 剪接增强子及其相应的 DNAme 变化。利用机器学习模型，我们能够从邻近的 CpG 准确预测外显子包含水平。这些 CpG 更可能与 RNA 结合及染色质修饰复合物的足迹重叠，而非转录因子。我们还报告了与每种基因型相关的独特基因表达谱；然而，差异表达基因与错误剪接的转录本并不重叠。相反，错误剪接的基因编码与调控这些差异表达基因的复合物相互作用的蛋白。由此可见，异常的 DNA 甲基化与剪接过程共同导致关键调控复合物的错误剪接，从而产生这些 AML 特有的异常基因表达谱。

### 第二部分 AI 大师评价

本研究旨在揭示 AML 中 DNA 甲基化基因与剪接因子共突变如何协同影响表观遗传调控。作者通过深度组学分析发现，IDH2 与 SRSF2 双突变引发独特的错误剪接及 DNA 甲基化改变，并利用机器学习模型建立了 CpG 与外显子剪接之间的预测关联。研究揭示了 DNA 甲基化异常与剪接失调之间的功能联系，为理解 AML 分子机制提供了新视角。该研究的创新在于跨层整合分析甲基化与剪接互动，但其模型的普适性与机制的因果验证仍需进一步探索。

---

## 25. 用于悬浮细胞高通量力学生物学研究的精密声流体平台

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481702)
**期刊：** Science advances
**PMID：** 41481702
**DOI：** 10.1126/sciadv.ady1136

### 第一部分 原文与翻译

**英文原标题：** Precision acoustofluidics for high-throughput mechanobiology in suspension cells.

> **英文摘要：**
> Mechanomodulation, the process of altering cellular behavior through applied mechanical forces, plays a critical role in physiological processes and has substantial implications for cancer therapy, immunology, and drug development. However, precise and efficient stimulation of nonadherent cells remains a major challenge, limiting the investigation of mechanotransduction pathways and the development of targeted therapeutics. Here, we developed an acoustofluidic platform named Suspension-cell Targeted Response to Excitation via Acoustofluidic Mechanomodulation (STREAM) to enable precise, high-throughput stimulation of suspension cells. STREAM accomplishes this using 101.14-megahertz high-frequency surface acoustic waves to deliver controlled mechanical stimulation at a throughput of 500,000 cells per minute. STREAM modulates intracellular calcium ion (Ca) signaling by activating mechanosensitive ion channels, triggering mitochondrial membrane disruption and tunable K562 leukemia cell apoptosis rates from 5.15 to 47.1%. STREAM provides a scalable, precise tool for studying mechanotransduction in suspension cells, with broad applications in cancer research, immunotherapy, and high-throughput drug screening.

> **中文摘要：**
> 力学调控（mechanomodulation）是通过施加机械力来改变细胞行为的过程，在生理过程中发挥关键作用，并对癌症治疗、免疫学及药物研发具有重要意义。然而，精确且高效地刺激非贴附性细胞仍是一个主要挑战，限制了对力学传导途径的研究及靶向治疗方法的发展。在本研究中，我们开发了一种名为“基于声流体力学调控的悬浮细胞靶向响应平台”（STREAM）的声流体系统，用于实现对悬浮细胞的精确、高通量刺激。STREAM 采用 101.14 兆赫的高频表面声波，以每分钟 50 万个细胞的通量提供受控的机械刺激。STREAM 通过激活机械敏感离子通道调节细胞内钙离子（Ca）信号，从而诱导线粒体膜破坏并可调控 K562 白血病细胞的凋亡率，范围为 5.15% 至 47.1%。STREAM 为研究悬浮细胞的力学传导提供了一种可扩展且精确的工具，在癌症研究、免疫治疗及高通量药物筛选中具有广泛应用前景。

### 第二部分 AI 大师评价

本研究建立了一个高频声流体平台 STREAM，实现了悬浮细胞在高通量条件下的精确力学刺激。该系统兼具 101.14 MHz 高频声波调控与定量化力学控制能力，成功验证了其对钙信号、线粒体功能与细胞凋亡的可调节效应。该方法拓展了非贴附性细胞力学生物学研究的边界，为肿瘤研究、免疫治疗及药物筛选提供了新型实验工具。其创新性在于将表面声波与流体力学集成用于细胞力学调控，但未来仍需评估其在复杂细胞系统中的普适性与长期效应。

---

## 26. 共同推进造血和淋巴系统肿瘤分类：惠及患者、医学与科学

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481391)
**期刊：** Blood
**PMID：** 41481391
**DOI：** 10.1182/blood.2025030689

### 第一部分 原文与翻译

**英文原标题：** Advancing the Classification of Hematolymphoid Neoplasms Together: For Patients, Medicine, and Science.

> **英文摘要：**
> A single, universally utilized tumor classification system is critical to ensure precision in patient care, clinical trial enrollment, and advancing therapy. Since the publication of the 3rd edition of the World Health Organization (WHO) classification in 2001, the hematology and hematopathology community had benefited from a single, widely accepted classification system. However, in 2022 two separate classifications of hematologic and lymphoid neoplasms emerged: the 5th edition of the WHO Classification of Hematolymphoid Tumours and the International Consensus Classification. This has created confusion and has resulted in a global call to action to return to a single classification system. In 2024, leaders of the Society of Hematopathology (SH) and European Association for Haematopathology (EA4HP) together with the leadership of WHO Classification of Tumours developed a plan to bridge the division and unite around the next edition of the WHO classification of hematologic and lymphoid tumours (WHO6). This plan entails convening a Classification Advancement Meeting (CAM), planned by SH and EA4HP with broad participation by pathologists, clinicians, and geneticists, to discuss and debate updates and changes to the existing classifications. Published conclusions of the CAM meeting will be available for independent consideration by the editorial board of WHO6. We are convinced that engagement of the broad community and leveraging global expertise to unite around WHO6 will critically benefit patients, medicine, and science.

> **中文摘要：**
> 建立一个统一、全球通用的肿瘤分类体系对于确保患者护理的精准性、临床试验的入组以及治疗进展至关重要。自2001年世界卫生组织（WHO）发布第三版分类以来，血液学和血液病理学界一直受益于一个被广泛接受的统一分类系统。然而，2022年出现了两个独立的血液及淋巴系统肿瘤分类：即WHO《造血和淋巴系统肿瘤分类》第五版和《国际共识分类》。这种分歧引发了混乱，并促使全球呼吁回归到单一分类体系。2024年，血液病理学会（SH）和欧洲血液病理学协会（EA4HP）的领导者，与WHO肿瘤分类项目组一道，制定了弥合分歧、共同推进下一版WHO造血和淋巴系统肿瘤分类（WHO6）的计划。该计划包括召开一次由SH和EA4HP主导、病理学家、临床医生及遗传学家广泛参与的分类进展会议（CAM），以讨论和审议现行分类的更新与修改。CAM会议的正式结论将公开发表，供WHO6编辑委员会独立参考。我们深信，通过凝聚全球专家力量并促进广泛的学术参与，共同推进WHO6的统一，将为患者、医学和科学带来重大益处。

### 第二部分 AI 大师评价

本文旨在回应当前造血和淋巴系统肿瘤在分类体系上的分裂状况，倡导回归并统一全球分类标准。作者以学会领导机构和WHO合作的计划为核心，提出通过召开分类进展会议（CAM）凝聚病理学、临床和遗传学界力量，共同推动WHO第六版分类的制定。其创新在于从国际协作和组织治理层面构建统一路线，以促进精准诊断与科学研究。文章反映了学界在面对标准分歧时的整合思维，但其执行仍需平衡不同地区和学术团体间的共识。

---

## 27. 携带 t(11;14)(CCND1;IGH) 易位的多发性骨髓瘤对维奈托克耐药的基因组学机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481388)
**期刊：** Blood
**PMID：** 41481388
**DOI：** 10.1182/blood.2025029996

### 第一部分 原文与翻译

**英文原标题：** Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).

> **英文摘要：**
> Multiple myeloma (MM) with t(11;14)(CCND1;IGH) remains the only subset sensitive to the BCL2 inhibitor venetoclax. Not all t(11;14)(CCND1;IGH) patients respond to treatment and some progress early after initial response. To investigate this, we interrogated 44 whole genome and exome sequencing data from 34 patients with t(11;14) MM treated with venetoclax. The presence of mutations in the RAS pathway was strongly associated with shortened progression-free survival (PFS) and was validated in an independent cohort of 21 MM patients. Presence of 1q gain was also associated with shorter PFS in patients without RAS mutations. In 10 patients with paired, pre- and post-venetoclax treatment samples, post-venetoclax progression was recurrently driven by the selection of genomic events in BCL2/MCL1 and RAS pathways and of high-risk features (e.g., loss of TP53 and CDKN2C). Overall, our study shows that comprehensive genomic profiling can identify most mechanisms underlying resistance to BCL2 inhibition in t(11;14)(CCND1;IGH) MM.

> **中文摘要：**
> 携带 t(11;14)(CCND1;IGH) 易位的多发性骨髓瘤（MM）仍是对 BCL2 抑制剂维奈托克敏感的唯一亚型。并非所有 t(11;14)(CCND1;IGH) 患者均对治疗有反应，部分患者在初始应答后即早期进展。为探究此现象，我们分析了 34 例接受维奈托克治疗的 t(11;14) 型 MM 患者的 44 份全基因组及外显子测序数据。结果显示，RAS 通路的突变与无进展生存期（PFS）显著缩短高度相关，这一发现亦在 21 例独立 MM 患者队列中得到验证。此外，在无 RAS 突变的患者中，1q 扩增的存在同样与较短的 PFS 相关。在 10 例具有配对的治疗前后样本的患者中，治疗后进展反复受到 BCL2/MCL1 及 RAS 通路基因组事件选择的驱动，以及高风险特征（如 TP53 和 CDKN2C 缺失）的影响。总体而言，本研究表明，全面的基因组分析可识别出 t(11;14)(CCND1;IGH) 型 MM 中 BCL2 抑制耐药的主要机制。

### 第二部分 AI 大师评价

本研究聚焦于 t(11;14)(CCND1;IGH) 型多发性骨髓瘤对维奈托克的耐药机制，结合全基因组与外显子测序揭示了 RAS 通路突变及 1q 扩增与较短无进展生存期密切相关。通过治疗前后样本对比，作者发现耐药的关键驱动来自 BCL2/MCL1 与 RAS 通路的选择性基因事件及高风险基因丢失。这项研究为理解维奈托克耐药的分子基础提供了深度证据，并提示基因组分型在个体化治疗决策中的应用价值。其局限在于样本量有限及对功能验证仍需进一步研究。

---

## 28. 通过双表位靶向恢复鲁索替尼敏感性的1型与2型CALR阳性骨髓增生性肿瘤超精准治疗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481383)
**期刊：** Blood
**PMID：** 41481383
**DOI：** 10.1182/blood.2024027897

### 第一部分 原文与翻译

**英文原标题：** Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity.

> **英文摘要：**
> Somatic frameshift mutations in the gene encoding calreticulin (CALR) give rise to myelofibrosis and are classified as Type 1 (del52) or Type 2 (ins5) according to the degree of wildtype sequence retained adjacent to the neopeptide, with each type conferring different clinical outcomes. Targeting strategies specific for Type 1 vs Type 2 mutations would have enormous clinical utility in the treatment and prevention of myelofibrosis as responses to tyrosine kinase inhibitors are not durable nor mutation-specific. Here we show that dual targeting of Type 1 (del52) mutant CALR with two monoclonal antibodies directed against distinct epitopes in CALR have significant advantages compared to single agent treatment in the eradication of primary megakaryocyte progenitors in vitro and in a humanized ossicle microenvironment leading to improved survival in xenograft models. Dual targeting was superior in blocking constitutive STAT5 and ERK phosphorylation induced by del52 and prevented accumulation of JAK2 phosphorylation, overcoming ruxolitinib resistance. In contrast, Type 2 mutations showed increased CALR dimerization and were partially resistant to antibody targeting but could be impacted by ruxolitinib triple combination. Together, our data demonstrate an ultra-precision medicine approach tailored to either Type 1 OR Type 2 mutation classes will be required for maximal efficacy and complete blockade of JAK/STAT signalling, with far-reaching implications for patient management.

> **中文摘要：**
> 编码钙网蛋白（CALR）的基因中发生的体细胞移码突变可导致骨髓纤维化，并根据新生肽邻近野生型序列保留的程度被分为1型（del52）或2型（ins5），每种类型均对临床结局产生不同影响。开发针对1型与2型突变的特异性靶向策略在骨髓纤维化的治疗与预防中具有巨大临床价值，因为对酪氨酸激酶抑制剂的反应既不持久，也非突变特异性。本研究显示，利用两种识别CALR不同表位的单克隆抗体对1型（del52）突变CALR进行双重靶向，相较于单一药物治疗，可在体外及人源化骨微环境中显著清除原代巨核细胞祖细胞，从而提高异种移植模型的存活率。双靶向疗法在阻断由del52诱导的持续性STAT5和ERK磷酸化方面表现更优，并可防止JAK2磷酸化积累，从而克服对鲁索替尼的耐药性。相比之下，2型突变显示出CALR二聚化增加，并对抗体靶向部分耐受，但可通过与鲁索替尼联合的三联方案产生影响。总体而言，我们的数据表明，实现最大疗效与完全阻断JAK/STAT信号通路需采用针对1型或2型突变类别量身定制的超精准医学策略，这对患者管理具有深远意义。

### 第二部分 AI 大师评价

本研究旨在探索针对不同类型CALR突变的超精准治疗策略，以克服现有酪氨酸激酶抑制剂疗效有限的问题。研究利用双表位单克隆抗体靶向1型CALR突变，显著改善了细胞清除效率与动物存活率，成功逆转鲁索替尼耐药性。该策略在信号通路阻断上优于单药治疗，揭示了表位协同强度在突变特异性治疗中的潜力。作者进一步指出，不同CALR突变类型需独立设计治疗方案，体现了精准医学的前沿理念，但临床转化与长期安全性仍需验证。

---

## 29. 源自造血干细胞和祖细胞的基因表达特征可预测骨髓纤维化患者的生存结局

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481381)
**期刊：** Blood
**PMID：** 41481381
**DOI：** 10.1182/blood.2025030094

### 第一部分 原文与翻译

**英文原标题：** A Stem and Progenitor Cell-Derived Gene Expression Signature is Prognostic for Survival in Myelofibrosis.

> **英文摘要：**
> We hypothesized that transcriptomic features among disease-driving hematopoietic stem and progenitor cells (HSPC) could improve the current paradigm for risk stratification in myelofibrosis (MF). Therefore, we performed bulk RNA-seq on blood from 358 MF patients split into training and test cohorts (ClinicalTrials.gov Identifier: NCT02760238). Single-cell (sc) RNA-seq data from Lin-CD34+ MF HSPCs were used to guide the development of a prognostic model trained on the bulk RNA-seq data. A NanoString assay was used to validate our final model in two independent cohorts of MF patients. We identified a 24-gene weighted-sum expression score (termed MPN24) that was prognostic of overall survival (OS). In two independent cohorts of 170 and 100 MF patients, MPN24-High scoring patients had worse 5-year OS compared to MPN24-Low scoring patients (25.5% vs 86.9%, HR = 9.81, P = 4.0e-11 and 23.5% vs 75.9%, HR = 6.40, P = 1.8e-7, respectively). MPN24-High was also associated with clinical, mutation and karyotypic features known to confer adverse risk in MF. The MPN24 score retained independent prognostic significance in multivariable analysis incorporating these covariates as well as existing risk stratification models including DIPSS, DIPSS Plus, MIPSS70, and MIPSS70 Plus v2.0, adding significant prognostic value to these risk stratification models (P = 1.6e-5, 4.0e-6, 1.5e-6, 5.4e-4, respectively). The MPN24 score was particularly useful in improving risk-stratification of DIPSS-Intermediate, and MIPSS70 Intermediate and High-risk patients. MPN24 is an HSPC-derived gene expression score that is associated with overall survival independent of clinical and genomic prognostic variables and improves risk stratification in MF.

> **中文摘要：**
> 我们假设，在驱动疾病发生的造血干细胞和祖细胞（HSPC）中存在的转录组特征，可能改进当前用于骨髓纤维化（MF）风险分层的范式。因此，我们对358例MF患者的血液样本进行了整体RNA测序（bulk RNA-seq），并将其分为训练队列和测试队列（ClinicalTrials.gov登记号：NCT02760238）。利用来源于Lin-CD34+ MF HSPC的单细胞（sc）RNA测序数据来指导在bulk RNA-seq数据上建立预后模型。随后使用NanoString检测在两个独立的MF患者队列中验证最终模型。我们确定了一个包含24个基因的加权求和表达评分（命名为MPN24），其可用于预测总体生存（OS）。在两个独立的MF患者队列（分别为170例和100例）中，高MPN24评分患者的5年OS显著低于低MPN24评分患者（分别为25.5%对86.9%，风险比HR=9.81，P=4.0×10⁻¹¹；以及23.5%对75.9%，HR=6.40，P=1.8×10⁻⁷）。高MPN24评分还与已知的不良临床、突变及核型特征相关。即使在包含这些协变量以及现有风险分层模型（如DIPSS、DIPSS Plus、MIPSS70和MIPSS70 Plus v2.0）的多变量分析中，MPN24评分仍保持独立的预后意义，并为这些风险分层模型提供了显著的附加预后价值（P分别为1.6×10⁻⁵、4.0×10⁻⁶、1.5×10⁻⁶、5.4×10⁻⁴）。MPN24评分在改进DIPSS中间风险组及MIPSS70中高风险患者的风险分层中尤为有用。MPN24是一种源自HSPC的基因表达评分，与总体生存独立相关，且可改进MF的风险分层体系。

### 第二部分 AI 大师评价

该研究旨在通过造血干细胞及祖细胞的转录组特征改善骨髓纤维化的风险评估。研究者利用358例患者的RNA测序数据构建并验证了一个由24个基因组成的加权表达评分MPN24，可显著预测总体生存。该评分在不同队列中均具有独立预后意义，并能够提升现有模型（如DIPSS、MIPSS70等）的风险分层性能。其创新点在于将单细胞与整体转录组信息结合以构建生物学驱动的预后指标，为精准个体化风险评估提供了新工具。然而，该模型的临床推广仍需在更大样本和多中心验证中进一步确认。

---

## 30. 儿童噬血性淋巴组织细胞增多症：当前的概念、诊断与治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481377)
**期刊：** Blood
**PMID：** 41481377
**DOI：** 10.1182/blood.2025028762

### 第一部分 原文与翻译

**英文原标题：** Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment.

> **英文摘要：**
> Pediatric hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome, characterized by heightened T-cell activation and overwhelming IFN-g production. Rather than a binary "primary" versus "secondary" framework, it is best conceptualized as a threshold phenomenon that occurs when combined genetic and environmental factors exceed a critical tipping point, leading to a recognizable clinical pattern of abnormal immunopathology. In addition to classic genetic cytotoxic defects, an increasing number of genetic lesions continue to be recognized related to HLH. Environmental triggers frequently include malignancy, infection, and rheumatologic disorders and identifying underlying factors driving HLH is a crucial component of evaluation. The revised HLH-2004 criteria are an important tool in promptly recognizing HLH, but clinical criteria may be fulfilled by other inflammatory disorders. Genetic and functional immune testing are complementary tools for diagnosis and establishing recurrence risk. Dexamethasone and etoposide remain cornerstones of initial therapy but are best utilized in an individualized, response-based manner with close monitoring of inflammatory markers. Newer, more targeted agents continue to emerge and are often critical additions for achieving disease control. Most patients with inherited cytotoxic defects and other select causes require hematopoietic cell transplant (HCT) for cure which should occur as soon as feasible once adequate, not perfect, HLH control aims to minimize risk of reactivation, infection, and toxicity. This review aims to highlight key advancements in defining, diagnosing, and treating HLH based on a growing understanding of HLH pathophysiology. We also provide perspectives on practical clinical approaches that may be useful for diagnosing and treating pediatric HLH.

> **中文摘要：**
> 儿童噬血性淋巴组织细胞增多症（HLH）是一种危及生命的高炎症综合征，其特征是T细胞过度激活和IFN-γ的异常大量产生。与其采用传统的“原发性”与“继发性”二元分类框架，不如将其理解为一种阈值现象：当遗传与环境因素的综合作用超过某个临界点时，就会引发具有特征性免疫病理学异常的临床表现。除经典的细胞毒性遗传缺陷外，越来越多与HLH相关的遗传病变被不断发现。环境诱因常包括恶性肿瘤、感染和风湿性疾病，识别驱动HLH发生的潜在因素是评估的重要组成部分。修订的HLH-2004诊断标准是快速识别HLH的重要工具，但这些临床标准也可能被其他炎症性疾病所满足。遗传学与免疫功能检测是诊断及评估复发风险的互补手段。地塞米松和依托泊苷仍是初始治疗的基石，但应个体化并基于反应调整方案，同时密切监测炎症指标。新的、更具靶向性的药物不断涌现，并在实现疾病控制方面发挥关键作用。大多数具有遗传性细胞毒缺陷或其他特定致病因素的患者需要造血干细胞移植（HCT）以实现治愈；一旦疾病得到充分（而非完全）控制，应尽早实施，以减少复发、感染和毒性风险。本综述旨在基于对HLH病理生理学的不断深入理解，总结其定义、诊断及治疗方面的最新进展，并提供有助于儿童HLH临床诊治的实用性思路。

### 第二部分 AI 大师评价

本综述系统梳理了儿童噬血性淋巴组织细胞增多症（HLH）的最新概念、诊断要点与治疗策略。文章强调HLH应被视为由多种遗传与环境因素交互导致的阈值性免疫失衡，而非简单的原发或继发分类。作者评估了现行HLH-2004标准的优缺点，提出遗传学与免疫功能检测的诊断互补价值，并总结了从糖皮质激素、依托泊苷到新型靶向药物的治疗进展。综述创新性地将病理机制理解与临床决策相结合，为个体化诊疗和移植时机选择提供了实践指导。其局限性在于部分结论尚待更多前瞻性临床证据验证。

---

## 31. 绘制体外人类发育性造血图谱以开辟再生医学新途径

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481376)
**期刊：** Blood
**PMID：** 41481376
**DOI：** 10.1182/blood.2024028063

### 第一部分 原文与翻译

**英文原标题：** Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine.

> **英文摘要：**
> The hematopoietic system performs essential functions for living organisms through a wide array of cell types, including immune cells for host defense, erythrocytes for oxygen transport and megakaryocytes involved in vascular and tissue repair. The adoptive transfer of mature blood cells and the transplantation of hematopoietic stem cells (HSCs) have been extensively exploited in clinical settings, for the treatment of inherited blood disorders as well as blood malignancies. In addition, blood cells are also preferential targets in the context of gene therapy, where they provide revolutionary treatments not only for classical hematologic diseases but also for novel and unexpected indications, such as inherited metabolic disorders. However, clinical bottlenecks remain, including the limited availability of suitably matched donor cells, the need for high cell doses, and the complexity of personalized manufacturing.Given their proliferative ability and capacity to generate any human cell type, human pluripotent stem cells (hPSCs), encompassing both embryonic stem cells (ESCs) and induced PSCs (iPSCs), represent a novel, potentially unlimited, easy-to-engineer source of either patient-specific or allogeneic blood cells for "off-the-shelf" cell therapies. In parallel, hPSC-derived blood cells enable in vitro modeling of diverse hematologic diseases and the identification of novel therapeutic targets. Recent advances describing protocols for the de novo generation of HSCs are opening new and exciting avenues for a broad application of hPSC-derived blood cells in both basic research and clinical medicine.

> **中文摘要：**
> 造血系统通过多种细胞类型在生物体中承担重要功能，包括用于宿主防御的免疫细胞、负责氧气运输的红细胞以及参与血管和组织修复的巨核细胞。成熟血细胞的过继转移和造血干细胞（HSCs）的移植已在临床广泛应用，用于治疗遗传性血液疾病以及血液恶性肿瘤。此外，在基因治疗的背景下，血细胞也是首选靶标，不仅为传统血液疾病提供革命性治疗，还为诸如遗传性代谢病等新颖且意料之外的适应症带来新的疗法。然而，临床上仍存在瓶颈，包括匹配供体细胞的有限可获得性、对高细胞剂量的需求以及个性化制备的复杂性。鉴于人多能干细胞（hPSCs）具有增殖能力并能产生任意人类细胞类型，它们——包括胚胎干细胞（ESCs）和诱导多能干细胞（iPSCs）——构成了一种新型、几乎无限、易于工程化的患者特异性或同种异体血细胞来源，为“现成型”细胞治疗提供可能。同时，hPSC来源的血细胞还可用于体外模拟多种血液疾病并发现新的治疗靶点。近期关于体外从头生成HSC的方案取得的进展，正在为hPSC来源血细胞在基础研究和临床医学中的广泛应用开启新的令人振奋的途径。

### 第二部分 AI 大师评价

该研究聚焦于利用人多能干细胞体外重建人类发育性造血过程，为再生医学与血液疾病治疗开辟新方向。作者综述了造血系统的功能及其在临床与基因治疗中的广泛应用，强调了供体细胞短缺和个性化制备复杂等瓶颈。文章指出，人多能干细胞因其无限增殖与分化潜能，成为可工程化血细胞的重要来源。近期的去 novo 造血干细胞生成技术进展，进一步推动了hPSC在疾病建模与细胞治疗中的应用。该文在整合现有研究基础上具有系统性与前瞻性，但仍需解决体外造血细胞功能成熟度及临床转化效率等技术挑战。

---

速递结束，祝您工作愉快！